<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019846</url>
  </required_header>
  <id_info>
    <org_study_id>SPA Trial vers. 1.1</org_study_id>
    <secondary_id>2020-005754-23</secondary_id>
    <nct_id>NCT05019846</nct_id>
  </id_info>
  <brief_title>SRT Versus SRT+ADT in Prostate Cancer</brief_title>
  <acronym>SPA</acronym>
  <official_title>Stereotactic Prostate Radiotherapy With or Without Androgen Deprivation Therapy, a Phase III, Multi-institutional Randomized-controlled Trial. The SPA Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marco Lorenzo Bonu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of&#xD;
      intermediate unfavorable and a subclass of high-risk patients treated with prostate&#xD;
      Stereotactic radiotherapy (SRT).&#xD;
&#xD;
      In intermediate unfavorable risk group, when choosing standard external beam radiotherapy,&#xD;
      short term ADT is superior in terms of biochemical disease free survival (bDFS) to EBRT&#xD;
      alone. In high risk disease, results of the combination therapy are even more clear. Prostate&#xD;
      SRT has been endorsed as option for primary radical treatment for prostate cancer. In such&#xD;
      patients, the benefit of ADT is still unknown and the decision is left to clinical judgement.&#xD;
&#xD;
      For these reasons, it seems to be relevant to propose a randomized, open label, phase III&#xD;
      clinical trial of prostate SBRT + 6 months ADT versus prostate SBRT alone in intermediate&#xD;
      unfavorable and a subgroup of high risk prostate cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>biochemical disease free survival</measure>
    <time_frame>outcome will be evaluated at the completion of 5 years of follow-up</time_frame>
    <description>form the date of the end of radiotherapy to the date of PSA meeting protocol criteria for biochemical relapse or last Follow-up visit. Outcome is mesured in months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>outcome will be evaluated at the completion of 5 years of follow-up</time_frame>
    <description>from the date of the end of radiotherapy to the date of relapse (any) or last Follow-up visit.Outcome is mesured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from local recurrence</measure>
    <time_frame>outcome will be evaluated at the completion of 5 years of follow-up</time_frame>
    <description>from the date of the end of radiotherapy to the date of local relapse or last Follow-up visit. Outcome is mesured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from regional recurrence</measure>
    <time_frame>outcome will be evaluated at the completion of 5 years of follow-up</time_frame>
    <description>from the date of the end of radiotherapy to the date of regional relapse or last Follow-up visit. Outcome is mesured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>freedom from distant metastasis</measure>
    <time_frame>outcome will be evaluated at the completion of 5 years of follow-up</time_frame>
    <description>from the date of the end of radiotherapy to the date of metastatic relapse or last Follow-up visit. Outcome is mesured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>outcome will be evaluated at the completion of 5 years of follow-up</time_frame>
    <description>from the date of the end of radiotherapy to the date of death 8any cause) or last Follow-up visit. Outcome is mesured in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life, prostate related quality of life in prostate cancer</measure>
    <time_frame>12 weeks after SRT, 3, 6 and 12 months after SRT</time_frame>
    <description>scored with questionnaire Expandend Prostate cancer Index Composite-26 (EPIC-26), score scale is 0-100 with higher scores representing better health related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life, prostate related quality of life questionnarire</measure>
    <time_frame>12 weeks after SRT, 3, 6 and 12 months after SRT</time_frame>
    <description>scored with questionnaire European organization for research and treatment of cancer PR 25, (EORTC PR 25), All of the scales and single-item measures range in score from 0 to 100. A high score for the Sexual Activity and Sexual Functioning scales represents a high level of functioning, whereas a high score for the Urinary, Bowel, and Hormonal Treatment Related symptoms scales and Incontinence Aid item represents a high level of symptomatology or problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients reported outcome, erectile function assessment,</measure>
    <time_frame>12 weeks after SRT, 3, 6 and 12 months after SRT</time_frame>
    <description>scored with questionnaire International Index of Erectile Function 5 (IIEF from 25 (best) to 5 (worse))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients reported outcome, prostate related symptoms assessment</measure>
    <time_frame>12 weeks after SRT, 3, 6 and 12 months after SRT</time_frame>
    <description>scored with questionnaire Internation Prostate syntoms scale (IPSS, from 0 (best) to 35 (worse))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician reported Acute Toxicity, assessed with CTCAE 5.0 scales</measure>
    <time_frame>from the beginning of treatment until 6 months after SRT</time_frame>
    <description>Outcome is mesured in 0-5 scale (higher scale worse toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician reported Late Toxicity, assessed with CTCAE 5.0 scales</measure>
    <time_frame>from 6 months after SRT 5 years of follow-up</time_frame>
    <description>Outcome is mesured in 0-5 scale (higher scale worse toxicity)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SRT+ADT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in ARM A will be treated with SRT on the prostate (consecutive days or at alternate days to a total dose of 36.25 Gy administered in 5 fraction (7.25 Gy/fraction) + LHRH analogue (Triptoreline 22.5 mg). An anti-androgen drug (es. Bicalutamide 50 mg) must be administered daily starting from 7 days before LHRH analogue administration to 10 days after to prevent the flare effect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRT alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in ARM B will be treated with SRT on prostate alone at a total dose of 36.25 Gy administered daily or on alternate days in 5 fraction (7.25 Gy/fraction).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin Embonate</intervention_name>
    <description>single administration before SRT starting</description>
    <arm_group_label>SRT+ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide 50 mg</intervention_name>
    <description>1 dose each day, 7 days before LHRH until 10 days after LHRH administration</description>
    <arm_group_label>SRT+ADT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of prostate acinar adenocarcinoma with a minimum of 10&#xD;
             biopsy cores taken&#xD;
&#xD;
          -  Prostate protocol MRI for local staging&#xD;
&#xD;
          -  Patients belonging to intermediate unfavorable group according to the D'Amico/NCCN&#xD;
             risk group classification:&#xD;
&#xD;
               -  -Grade group 3 or/and&#xD;
&#xD;
               -  -2-3 risk factors for intermediate category (PSA 10-20 ng/ml/ Grade group 2-3/&#xD;
                  cT2b cT2c) or/and&#xD;
&#xD;
               -  -biopsy cores positive ≥50%&#xD;
&#xD;
          -  Patients belonging to a subclass of high risk group according to the D'Amico/NCCN risk&#xD;
             group classification:&#xD;
&#xD;
               -  -ISUP group 4 (GS 4+4, 3+5, 5+3) or&#xD;
&#xD;
               -  -cT3a stage or&#xD;
&#xD;
               -  PSA&gt;20&#xD;
&#xD;
          -  Eastern Coooperative Oncology Group (ECOG) PS 0-2&#xD;
&#xD;
          -  Ability of the patient to understand and sign a written informed consent document&#xD;
&#xD;
          -  Ability and willingness to comply with patients reported outcome questionnaires&#xD;
             schedule during the study time&#xD;
&#xD;
          -  IPSS 0-15&#xD;
&#xD;
          -  Prostate Volume less than 100cc&#xD;
&#xD;
          -  PSA must be dosed maximum 60 days before randomization&#xD;
&#xD;
          -  No pathologic lymph nodes and distant metastasis on PET (fluorocholine) scan or CT&#xD;
             scan+bone scan.&#xD;
&#xD;
          -  Contraceptive measures for patients with partners with reproductive potential must be&#xD;
             explained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Malignant tumors in the previous 2 years excluding non melanoma cancers of&#xD;
             the skin. If a patient presents an anamnesis of malignancy (excluding non melanoma&#xD;
             skin cancers) it must be free from disease since 24 months at the time of enrollement.&#xD;
&#xD;
          -  Previous prostate surgery other than TURP (at least 6 weeks prior to start of SBRT).&#xD;
&#xD;
          -  Previous pelvic RT&#xD;
&#xD;
          -  Prior androgen deprivation therapy (excluding 5alpha reductase inhibitors)&#xD;
&#xD;
          -  Any prior active treatment for prostate cancer; patients on previous active&#xD;
             surveillance are eligible if inclusion criteria are met&#xD;
&#xD;
          -  Active severe inflammatory bowel disease&#xD;
&#xD;
          -  Bilateral hip prothesis or any implant that could seriously interfere with dosimetric&#xD;
             calculations&#xD;
&#xD;
          -  Age &gt;80 years.&#xD;
&#xD;
          -  cT4a, cT3b or pelvic lymph node involvement&#xD;
&#xD;
          -  Controindication or hypersensitivity to the use of Triptoreline&#xD;
&#xD;
          -  5alpha reductase inhibitors not discontinued 4 weeks prior to randomization&#xD;
&#xD;
          -  History of bone fractures and fall&#xD;
&#xD;
          -  Risk factors for abnormal heart rhythms or QT prolongation.&#xD;
&#xD;
          -  Use of concomitant medications that prolong the QT/QTc interval&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>prostate cancer patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Triggiani, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Brescia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Lorenzo Bonù, MD</last_name>
    <phone>+390303995285</phone>
    <email>marco.bonu@unibs.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>ASST Spedali Civili of Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Lorenzo Bonù, MD</last_name>
      <phone>+390303995285</phone>
      <email>dm.radioterapiabs@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Marco Lorenzo Bonu</investigator_full_name>
    <investigator_title>MD, Scientific coordinator</investigator_title>
  </responsible_party>
  <keyword>SRT</keyword>
  <keyword>ADT</keyword>
  <keyword>SBRT</keyword>
  <keyword>high risk prostate cancer</keyword>
  <keyword>unfavourable intermediate risk prostate cancer</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Concurrently with the publication of study results concerning efficacy, we will deliver a completely deidentified data set to an appropriate data archive for sharing purposes.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Concurrently with the publication of study results concerning efficacy, we will deliver a completely deidentified data set to an appropriate data archive for sharing purposes.</ipd_time_frame>
    <ipd_access_criteria>explicit request</ipd_access_criteria>
    <ipd_url>http://dm.radioterapiabs@gmail.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

